Oral Antibiotics Market Report and Forecast 2025-2034
Description
The global oral antibiotics market size was valued at USD 18.50 Billion in 2024, driven by the rising incidence of infectious diseases across the globe. The market is expected to grow at a CAGR of 2.50% during the forecast period of 2025-2034, with the values likely to rise from USD 18.96 Billion in 2025 to USD 23.68 Billion by 2034.
Oral Antibiotics: Introduction
Oral antibiotics refer to medical drugs such as tablets and capsules that are administered orally and are used to treat mild to moderate infections in the body. They eliminate the risk of canula-related infections to enhance the cost-effectiveness while effectively treating infectious diseases. Moreover, oral antibiotics are typically used to kill microbes in the body.
Global Oral Antibiotics Market Analysis
With the rising incidence of chronic diseases like influenza and tuberculosis, the oral antibiotics market demand has grown in the historical period. The growing prevalence of urinary tract infections (UTIs), especially in women, has significantly boosted the demand for oral antibiotics such as Fosfomycin and ceftriaxone, among others.
With the sudden COVID-19 outbreak, the approvals for oral antibiotics by government bodies have seen an upswing. This can be attributed to enhance the treatment options for infectious diseases. In September 2023, the FDA granted its approval for Canada based Appili Therapeutics' liquid form of antibiotic drug called metronidazole. This liquid oral form is an effective alternative for those who are unable to administer antibiotics through injections or pills.
The oral antibiotics market growth is further driven by a profound emphasis on battling antibiotic resistance. A global non-profit organization CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded the researchers from the University of Melbourne with a whopping USD 1.75 million to develop an oral therapeutic that can restore the activity of antibiotics used to treat pneumonia. Such investments are expected to foster innovation and bring effective treatment alternatives for patients across the globe.
Global Oral Antibiotics Market Segmentation
The EMR’s report titled “Oral Antibiotics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Class
The North America, particularly the United States, has dominated the oral antibiotics market share in the historical period. The market share can be accredited to the increasing number of drug approvals by the government bodies like the FDA. Furthermore, the region is experiencing several mergers and acquisitions wherein the healthcare giants are acquiring smaller companies to foster innovation and growth.
The Asia Pacific region is anticipated to experience a surge in the oral therapeutics market value, aided by improving research and healthcare infrastructure. In addition, the rising privatization in countries like India is driving the market forward with rapid adoption of latest technologies. There is immense focus on combating antibiotic resistance, with new seminars being arranged to educate the scientific community.
Europe, with a robust research infrastructure, is another centre of innovation for the oral antibiotics market. It is a huge market for oral antibiotic consumption, with a substantial amount of geriatric population, that is more prone to chronic diseases. The presence of several academic institutions and prominent pharmaceutical companies plays a major role in contributing to the significant market size.
Global Oral Antibiotics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Oral Antibiotics: Introduction
Oral antibiotics refer to medical drugs such as tablets and capsules that are administered orally and are used to treat mild to moderate infections in the body. They eliminate the risk of canula-related infections to enhance the cost-effectiveness while effectively treating infectious diseases. Moreover, oral antibiotics are typically used to kill microbes in the body.
Global Oral Antibiotics Market Analysis
With the rising incidence of chronic diseases like influenza and tuberculosis, the oral antibiotics market demand has grown in the historical period. The growing prevalence of urinary tract infections (UTIs), especially in women, has significantly boosted the demand for oral antibiotics such as Fosfomycin and ceftriaxone, among others.
With the sudden COVID-19 outbreak, the approvals for oral antibiotics by government bodies have seen an upswing. This can be attributed to enhance the treatment options for infectious diseases. In September 2023, the FDA granted its approval for Canada based Appili Therapeutics' liquid form of antibiotic drug called metronidazole. This liquid oral form is an effective alternative for those who are unable to administer antibiotics through injections or pills.
The oral antibiotics market growth is further driven by a profound emphasis on battling antibiotic resistance. A global non-profit organization CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) has awarded the researchers from the University of Melbourne with a whopping USD 1.75 million to develop an oral therapeutic that can restore the activity of antibiotics used to treat pneumonia. Such investments are expected to foster innovation and bring effective treatment alternatives for patients across the globe.
Global Oral Antibiotics Market Segmentation
The EMR’s report titled “Oral Antibiotics Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:
Market Breakup by Class
- Penicillin’s
- Cephalosporins
- Macrolides
- Fluoroquinolones
- Tetracyclines
- Sulfonamides and Trimethoprim
- Others
- Broad Spectrum Antibiotics
- Mid and Narrow Spectrum Antibiotics
- Respiratory Infections
- Urinary Tract Infections (UTIs)
- Skin Infections
- Gastrointestinal Infections
- Sexually Transmitted Infections (STIs)
- Others
- Hospital Pharmacies
- Retail Pharmacies and Drug Stores
- Online Pharmacies
- Others
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
The North America, particularly the United States, has dominated the oral antibiotics market share in the historical period. The market share can be accredited to the increasing number of drug approvals by the government bodies like the FDA. Furthermore, the region is experiencing several mergers and acquisitions wherein the healthcare giants are acquiring smaller companies to foster innovation and growth.
The Asia Pacific region is anticipated to experience a surge in the oral therapeutics market value, aided by improving research and healthcare infrastructure. In addition, the rising privatization in countries like India is driving the market forward with rapid adoption of latest technologies. There is immense focus on combating antibiotic resistance, with new seminars being arranged to educate the scientific community.
Europe, with a robust research infrastructure, is another centre of innovation for the oral antibiotics market. It is a huge market for oral antibiotic consumption, with a substantial amount of geriatric population, that is more prone to chronic diseases. The presence of several academic institutions and prominent pharmaceutical companies plays a major role in contributing to the significant market size.
Global Oral Antibiotics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Pfizer Inc.
- Novartis AG
- GlaxoSmithKline plc (GSK)
- Merck & Co., Inc.
- AstraZeneca plc.
- Roche Holding AG
- Bayer AG
- Johnson & Johnson
- Sanofi
- Alkem Laboratories Ltd.
- Cipla Ltd.
- Abbott Laboratories
- Lupin
- Sun Pharmaceutical Industries Ltd.
- Teva Pharmaceutical Industries Ltd.
*Please Note:* The report will take 5 business days to complete, after order confirmation.
Table of Contents
350 Pages
- 1 Preface
- 1.1 Objectives of the Study
- 1.2 Key Assumptions
- 1.3 Report Coverage – Key Segmentation and Scope
- 1.4 Research Methodology
- 2 Executive Summary
- 3 Global Oral Antibiotics Market Overview
- 3.1 Global Oral Antibiotics Market Historical Value (2018-2024)
- 3.2 Global Oral Antibiotics Market Forecast Value (2025-2034)
- 4 Global Oral Antibiotics Market Landscape
- 4.1 Global Oral Antibiotics Developers Landscape
- 4.1.1 Analysis by Year of Establishment
- 4.1.2 Analysis by Company Size
- 4.1.3 Analysis by Region
- 4.2 Global Oral Antibiotics Product Landscape
- 4.2.1 Analysis by Class
- 4.2.2 Analysis by Applications
- 5 Global Oral Antibiotics Market Dynamics
- 5.1 Market Drivers and Constraints
- 5.2 SWOT Analysis
- 5.3 Porter’s Five Forces Model
- 5.4 Key Demand Indicators
- 5.5 Key Price Indicators
- 5.6 Industry Events, Initiatives, and Trends
- 5.7 Value Chain Analysis
- 6 Global Oral Antibiotics Market Segmentation
- 6.1 Global Oral Antibiotics Market by Class
- 6.1.1 Market Overview
- 6.1.2 Penicillin’s
- 6.1.3 Cephalosporins
- 6.1.4 Macrolides
- 6.1.5 Fluoroquinolones
- 6.1.6 Tetracyclines
- 6.1.7 Sulfonamides and Trimethoprim
- 6.1.8 Others
- 6.2 Global Oral Antibiotics Market by Spectrum of Antibiotics
- 6.2.1 Market Overview
- 6.2.2 Broad Spectrum Antibiotics
- 6.2.3 Mid and Narrow Spectrum Antibiotics
- 6.3 Global Oral Antibiotics Market by Applications
- 6.3.1 Market Overview
- 6.3.2 Respiratory Infections
- 6.3.3 Urinary Tract Infections (UTIs)
- 6.3.4 Skin Infections
- 6.3.5 Gastrointestinal Infections
- 6.3.6 Sexually Transmitted Infections (STIs)
- 6.3.7 Others
- 6.4 Global Oral Antibiotics Market by Distribution Channel
- 6.4.1 Market Overview
- 6.4.2 Hospital Pharmacies
- 6.4.3 Retail Pharmacies and Drug Stores
- 6.4.4 Online Pharmacies
- 6.4.5 Others
- 6.5 Global Oral Antibiotics Market by Region
- 6.5.1 Market Overview
- 6.5.2 North America
- 6.5.3 Europe
- 6.5.4 Asia Pacific
- 6.5.5 Latin America
- 6.5.6 Middle East and Africa
- 7 North America Oral Antibiotics Market
- 7.1 Market Share by Country
- 7.2 United States of America
- 7.3 Canada
- 8 Europe Oral Antibiotics Market
- 8.1 Market Share by Country
- 8.2 United Kingdom
- 8.3 Germany
- 8.4 France
- 8.5 Italy
- 8.6 Others
- 9 Asia Pacific Oral Antibiotics Market
- 9.1 Market Share by Country
- 9.2 China
- 9.3 Japan
- 9.4 India
- 9.5 ASEAN
- 9.6 Australia
- 9.7 Others
- 10 Latin America Oral Antibiotics Market
- 10.1 Market Share by Country
- 10.2 Brazil
- 10.3 Argentina
- 10.4 Mexico
- 10.5 Others
- 11 Middle East and Africa Oral Antibiotics Market
- 11.1 Market Share by Country
- 11.2 Saudi Arabia
- 11.3 United Arab Emirates
- 11.4 Nigeria
- 11.5 South Africa
- 11.6 Others
- 12 Patent Analysis
- 12.1 Analysis by Type of Patent
- 12.2 Analysis by Publication year
- 12.3 Analysis by Issuing Authority
- 12.4 Analysis by Patent Age
- 12.5 Analysis by CPC Analysis
- 12.6 Analysis by Patent Valuation
- 12.7 Analysis by Key Players
- 13 Grants Analysis
- 13.1 Analysis by year
- 13.2 Analysis by Amount Awarded
- 13.3 Analysis by Issuing Authority
- 13.4 Analysis by Grant Application
- 13.5 Analysis by Funding Institute
- 13.6 Analysis by NIH Departments
- 13.7 Analysis by Recipient Organization
- 14 Clinical Trials Analysis
- 14.1 Analysis by Trial Registration Year
- 14.2 Analysis by Trial Status
- 14.3 Analysis by Trial Phase
- 14.4 Analysis by Therapeutic Area
- 14.5 Analysis by Geography
- 15 Funding and Investment Analysis
- 15.1 Analysis by Funding Instances
- 15.2 Analysis by Type of Funding
- 15.3 Analysis by Funding Amount
- 15.4 Analysis by Leading Players
- 15.5 Analysis by Leading Investors
- 15.6 Analysis by Geography
- 16 Partnership and Collaborations Analysis
- 16.1 Analysis by Partnership Instances
- 16.2 Analysis by Type of Partnership
- 16.3 Analysis by Leading Players
- 16.4 Analysis by Geography
- 17 Regulatory Framework
- 17.1 Regulatory Overview
- 17.1.1 US FDA
- 17.1.2 EU EMA
- 17.1.3 INDIA CDSCO
- 17.1.4 JAPAN PMDA
- 17.1.5 Others
- 18 Supplier Landscape
- 18.1 Pfizer Inc.
- 18.1.1 Financial Analysis
- 18.1.2 Product Portfolio
- 18.1.3 Demographic Reach and Achievements
- 18.1.4 Mergers and Acquisitions
- 18.1.5 Certifications
- 18.2 Novartis AG
- 18.2.1 Financial Analysis
- 18.2.2 Product Portfolio
- 18.2.3 Demographic Reach and Achievements
- 18.2.4 Mergers and Acquisitions
- 18.2.5 Certifications
- 18.3 GlaxoSmithKline plc (GSK)
- 18.3.1 Financial Analysis
- 18.3.2 Product Portfolio
- 18.3.3 Demographic Reach and Achievements
- 18.3.4 Mergers and Acquisitions
- 18.3.5 Certifications
- 18.4 Merck & Co., Inc.
- 18.4.1 Financial Analysis
- 18.4.2 Product Portfolio
- 18.4.3 Demographic Reach and Achievements
- 18.4.4 Mergers and Acquisitions
- 18.4.5 Certifications
- 18.5 AstraZeneca plc.
- 18.5.1 Financial Analysis
- 18.5.2 Product Portfolio
- 18.5.3 Demographic Reach and Achievements
- 18.5.4 Mergers and Acquisitions
- 18.5.5 Certifications
- 18.6 Roche Holding AG
- 18.6.1 Financial Analysis
- 18.6.2 Product Portfolio
- 18.6.3 Demographic Reach and Achievements
- 18.6.4 Mergers and Acquisitions
- 18.6.5 Certifications
- 18.7 Bayer AG
- 18.7.1 Financial Analysis
- 18.7.2 Product Portfolio
- 18.7.3 Demographic Reach and Achievements
- 18.7.4 Mergers and Acquisitions
- 18.7.5 Certifications
- 18.8 Johnson & Johnson
- 18.8.1 Financial Analysis
- 18.8.2 Product Portfolio
- 18.8.3 Demographic Reach and Achievements
- 18.8.4 Mergers and Acquisitions
- 18.8.5 Certifications
- 18.9 Sanofi
- 18.9.1 Financial Analysis
- 18.9.2 Product Portfolio
- 18.9.3 Demographic Reach and Achievements
- 18.9.4 Mergers and Acquisitions
- 18.9.5 Certifications
- 18.10 Alkem Laboratories Ltd.
- 18.10.1 Financial Analysis
- 18.10.2 Product Portfolio
- 18.10.3 Demographic Reach and Achievements
- 18.10.4 Mergers and Acquisitions
- 18.10.5 Certifications
- 18.11 Cipla Ltd.
- 18.11.1 Financial Analysis
- 18.11.2 Product Portfolio
- 18.11.3 Demographic Reach and Achievements
- 18.11.4 Mergers and Acquisitions
- 18.11.5 Certifications
- 18.12 Abbott Laboratories
- 18.12.1 Financial Analysis
- 18.12.2 Product Portfolio
- 18.12.3 Demographic Reach and Achievements
- 18.12.4 Mergers and Acquisitions
- 18.12.5 Certifications
- 18.13 Lupin
- 18.13.1 Financial Analysis
- 18.13.2 Product Portfolio
- 18.13.3 Demographic Reach and Achievements
- 18.13.4 Mergers and Acquisitions
- 18.13.5 Certifications
- 18.14 Sun Pharmaceutical Industries Ltd.
- 18.14.1 Financial Analysis
- 18.14.2 Product Portfolio
- 18.14.3 Demographic Reach and Achievements
- 18.14.4 Mergers and Acquisitions
- 18.14.5 Certifications
- 18.15 Teva Pharmaceutical Industries Ltd.
- 18.15.1 Financial Analysis
- 18.15.2 Product Portfolio
- 18.15.3 Demographic Reach and Achievements
- 18.15.4 Mergers and Acquisitions
- 18.15.5 Certifications
- 19 Global Oral Antibiotics Market - Distribution Model (Additional Insight)
- 19.1 Overview
- 19.2 Potential Distributors
- 19.3 Key Parameters for Distribution Partner Assessment
- 20 Key Opinion Leaders (KOL) Insights (Additional Insight)
- 21 Company Competitiveness Analysis (Additional Insight)
- 21.1 Very Small Companies
- 21.2 Small Companies
- 21.3 Mid-Sized Companies
- 21.4 Large Companies
- 21.5 Very Large Companies
- 22 Payment Methods (Additional Insight)
- 22.1 Government Funded
- 22.2 Private Insurance
- 22.3 Out-of-Pocket
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
